Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Discount contracts: Germany's misguided attempt at cost-cutting

This article was originally published in Scrip

Executive Summary

It is extremely easy to be cynical about what are often perceived to be immense profits generated by the research-based pharmaceutical industry. Perhaps in the past it was easy to fall in line with general criticisms, partly because of reciprocally beneficial deals made with between manufacturers and companies or medical professionals. However, the introduction of self regulation and codes of practice have largely eradicated these agreements. Increasingly, profits are being ploughed back into research and development as the emergence of new chemical entities dries up.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts